CPB vs IKT · P/E 12, rev $10.25B vs $215.2M cap
Campbell’s Co (CPB) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
Campbell’s Co (CPB) is a packaged foods company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported CPB revenue for 2025-08-03 was $10.25B. Net income was $602.0M. CPB currently screens at market cap $6.46B and trailing P/E 11.8.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
CPB currently screens at market cap $6.46B and trailing P/E 11.8. IKT currently screens at market cap $215.2M.
Not investment advice. Open the CPB and IKT stock pages for the full models.
Not investment advice.